Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $1.57
Latest analyst grade actions
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 26.75 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 12.79 | Oscillator | Buy |
| Williams %R (14) | -91.04 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.54 (Hist -0.06) | Oscillator | Strong Sell |
| Average Directional Index (14) | 33.88 (+DI 11.7 / -DI 32.3) | Trend | Strong Sell |
| EMA 20 | 2.35 | MA | Strong Sell |
| SMA 20 | 2.43 | MA | Strong Sell |
| EMA 50 | 3.00 | MA | Strong Sell |
| SMA 50 | 3.27 | MA | Strong Sell |
| SMA 200 | 4.28 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | BSEM | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.9x | -4.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.8x | EPS est. -1.90 | In line |
| Price / Book | 1.0x | -12.5x | Discount |
| Price / Sales | -0.5x | 2.8x | Discount |
| EV / EBITDA | -1.1x | -31.2x | Discount |
| Return on equity | -76.1% | — | Weak |
| Gross margin | 113.9% | 86.8% | Above hist. |
| Debt / Equity | 0.04 | -1.08 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -3.11 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 424B3 | Oct 13, 2026 | 2026-10-13 16:21:55 | View |
| EFFECT | Oct 9, 2026 | 2026-10-13 00:15:19 | View |
| 4 | Oct 9, 2026 | 2026-10-09 16:30:06 | View |
| 4 | Oct 9, 2026 | 2026-10-09 16:30:03 | View |
| D | Oct 9, 2026 | 2026-10-09 16:10:30 | View |
| S-8 | Oct 6, 2026 | 2026-10-06 17:23:26 | View |
| S-1 | Oct 2, 2026 | 2026-10-02 17:26:59 | View |
| 8-K | Sep 30, 2026 | 2026-09-30 16:48:24 | View |
| EFFECT | Sep 29, 2026 | 2026-09-30 00:15:28 | View |
| 424B3 | Sep 29, 2026 | 2026-09-29 16:56:20 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 7, 26 | Smith-Van Vurst Andrew | director, 10 percent owner, officer: Chief Operating Officer | M-Exempt | 250,000 @ $2.00 | $500.0K |
| Oct 7, 26 | Smith-Van Vurst Andrew | director, 10 percent owner, officer: Chief Operating Officer | M-Exempt | 250,000 @ $2.00 | $500.0K |
| Oct 7, 26 | Matuszewski Jason | director, 10 percent owner, officer: Chief Executive Officer | M-Exempt | 250,000 @ $2.00 | $500.0K |
| Oct 7, 26 | Matuszewski Jason | director, 10 percent owner, officer: Chief Executive Officer | M-Exempt | 250,000 @ $2.00 | $500.0K |
| Sep 15, 26 | Poe Brandon | officer: Chief Financial Officer | M-Exempt | 1,694 | — |
| Sep 15, 26 | Poe Brandon | officer: Chief Financial Officer | M-Exempt | 1,694 | — |
| Sep 17, 26 | Smith-Van Vurst Andrew | director, 10 percent owner, officer: Chief Operating Officer | M-Exempt | 9,574 | — |
| Sep 15, 26 | Smith-Van Vurst Andrew | director, 10 percent owner, officer: Chief Operating Officer | M-Exempt | 7,622 | — |
Stock news · updated daily
Leadership investment supports expanded hospital commercial push PR Audio: POMPANO BEACH, Fla., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at an exercise price of $2.00 per share, for a total of 500,000 shares and an aggregate purchase price of approximately $1 million.
Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Analyst Ratings This is a breakdown of
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies PR Audio: POMPANO BEACH, Fla., October 1, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issued one notice of allowance for additional patent applications.
POMPANO BEACH, Fla., September 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company's common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.50 | -0.52 | Miss -4.0% | $7.90M |
| May 14, 2026 | -0.28 | -0.52 | Miss -85.7% | $6.14M |
| Mar 24, 2026 | 0.02 | -0.67 | Miss -3450.0% | $10.10M |
| Nov 13, 2025 | 0.02 | 0.03 | Beat 50.0% | $10.47M |
| Aug 14, 2025 | 0.32 | -0.03 | Miss -109.4% | $49.30M |
| May 12, 2025 | 1.25 | 0.17 | Miss -86.4% | $72.50M |